Meeting Unmet Need and Increasing Contraceptive Options and Services with Postpartum Family Planning

Roy Jacobstein, MD, MPH
EngenderHealth
FIGO panel, Post-partum contraception with a focus on post-partum IUDs
Rome, Italy, 10 October 2012
Why is postpartum (PP) family planning (FP) important?

Clinical / program definitions

How is PP FP faring? (opportunities / challenges)

What’s the “payoff” in increasing PP FP?

Focus on clinical FP methods, especially IUDs, as lead-in to next three presentations
Why PP FP is important: High motivation, high unmet need

- 95% of women in 1st year post partum want to delay another pregnancy at least two years (space) or avoid future pregnancies (limit)*
- Unmet need for modern contraception is very high:
  - 222,000,000 women (26%) in developing countries have unmet need**
  - In world’s 69 poorest countries, unmet need is growing
- 40% of total unmet need for modern FP is in 1st year postpartum**
- Short inter-pregnancy intervals → low birth weights & pre-term births
- Ovulation occurs as early as 25 days PP in non-breastfeeding women
- Women and providers often unaware of risk of next pregnancy

**Ross and Winfrey "Contraceptive use, intention to use, and unmet need during the extended postpartum period," Intl FP Perspectives, 2001.
High unmet need, low use

Source: Ross and Winfrey “Contraceptive use, Intention to use, and unmet need during the extended postpartum period, Intl FP Perspectives, 2001.
... FP use and method mix among women giving birth in previous 12 months, selected country examples

The four long-acting and permanent methods (LA/PMs) Characteristics and PP FP service requirements

Characteristics:
- Highly effective
- Most cost-effective over time
- Popular when accessible
  (good fit with reproductive intentions)

Clinical methods, thus require:
- Skilled, motivated, enabled providers
  > “No provider, no program”
- Suitable service setting
- Essential instruments and supplies
- Training and supervision systems
- Voluntary, informed choice (always)

LAPMs in the extended postpartum period (0-1yr):
An opportune time for service access and provision

<table>
<thead>
<tr>
<th>Method</th>
<th># of unintended pregnancies among 1,000 women in 1st year of typical use</th>
</tr>
</thead>
<tbody>
<tr>
<td>No method</td>
<td>850</td>
</tr>
<tr>
<td>Withdrawal</td>
<td>220</td>
</tr>
<tr>
<td>Female condom</td>
<td>210</td>
</tr>
<tr>
<td>Male condom</td>
<td>180</td>
</tr>
<tr>
<td>Pill</td>
<td>90</td>
</tr>
<tr>
<td>Injectable</td>
<td>60</td>
</tr>
<tr>
<td>IUD</td>
<td>8 / 2 (Cu-T / LNG-IUS)</td>
</tr>
<tr>
<td>Female sterilization</td>
<td>5</td>
</tr>
<tr>
<td>Vasectomy</td>
<td>1.5</td>
</tr>
<tr>
<td>Implant</td>
<td>0.5</td>
</tr>
</tbody>
</table>

## Unit costs of modern methods

### Typical unit costs in public sector FP programs

<table>
<thead>
<tr>
<th>Method</th>
<th>Unit Cost</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male condom</td>
<td>$0.025</td>
</tr>
<tr>
<td>Pill</td>
<td>$0.21</td>
</tr>
<tr>
<td><strong>IUD</strong></td>
<td>$0.37</td>
</tr>
<tr>
<td>Female condom</td>
<td>$0.77</td>
</tr>
<tr>
<td>Injectable</td>
<td>$0.87</td>
</tr>
<tr>
<td>Male sterilization</td>
<td>$4.95</td>
</tr>
<tr>
<td>Sino-implant (II)</td>
<td>~$8.00</td>
</tr>
<tr>
<td>Female sterilization</td>
<td>$9.09</td>
</tr>
<tr>
<td><strong>Implant (Jadelle; Implanon)</strong></td>
<td>$18.00*</td>
</tr>
</tbody>
</table>

Ross, Weissman, and Stover, 2009  
*latest USAID commodity price, 2012*
Cost-effectiveness per couple-year of protection

Service Delivery Cost/CYP


* Costs include the commodity, materials and supplies, labor time inputs and annual staff salaries. The height of each bar shows the average value of costs per CYP across 13 USAID priority countries.
The IUD is the most commonly used temporary method in the world*
- 169 million MWRA (14% MWRA)

Wide regional and country differences, e.g.:
- 42% in Central Asia; 38% Eastern Asia (Vietnam, 44%, China, 41%)
- 12% in Northern Europe; 11% in Western Europe (France, 23%; Italy, 6%)
- 5% in Northern America (in U.S., 5% and rising: Mirena)

“Underutilized” in Southern Asia (2%) and sub-Saharan Africa (0.5%)
- India, 1.7% (3.7 million women); Bangladesh, 0.3%
- Kenya, 1.6%
- Nigeria & South Africa, 1.0%
- Ethiopia & DRC, 0.2%; Zambia, 0.1%

Source: UN Dept of Economic and Social Affairs, Population Div., 2012. "World Contraceptive Use, 2011"
Opportunities to provide / receive FP are increasing
- 88% of women delivering in previous 5 years received antenatal care*
- 59% delivered in a health facility (50% in sub-Saharan Africa)*

Task-shifting / task-sharing to midlevel providers is long-proven and widely-accepted (midwives, nurses, clinical officers: LARCs)

Convenient for women (and programs?)

Cost-effective for FP programs, e.g., for IUD:
- Immediate post-placental IUD $2.14-$3.37
- Before discharge $2.79-$3.97
- Interval $3.75-$4.70

*Source: StatCompiler Macro. 2012, 50 countries with a Demographic and Health Survey (DHS) in past 5 years.
Many barriers to improved FP access, quality & use (whether PP, IUD, other methods, other times)

Barriers to effective PP IUD and other FP services

- Structure of MCH and FP services
- Myths and misperceptions
- Exaggerated provider concerns re STI, PID, infertility, expulsion
- Training factors
- Inappropriate eligibility criteria
- Norms where births occur
- Provider bias
- Lack of skills
- Poor CPI

“No provider, no program”
- Adequate caseload for training and to maintain skills
- Supervision

Integration often “easier said than done”:
- “Will it negatively affect my already-existing other program (e.g., safe delivery or immunization)?”
- “Whose job is it?”
- “Can I do it?”
- “Is this a reward, or a punishment?”

“Who cares?” (enough to do something about it, every day):
- “Champions needed”
The “payoff” if choice of / access to PP FP is increased and unmet need for FP is met

- 222 million women in developing countries have unmet need for modern FP*
- 40% of unmet need is in first year PP**
- Meeting this unmet need would prevent 54 million unintended pregnancies*, incl:
  - 26,000,000 fewer abortions
  - ~ 80,000 fewer maternal deaths
  - 2,400,000 fewer serious morbidities
  - 1,100,000 fewer infant deaths
  - > 300,000 fewer children lose mother
- Many other individual, family, societal and national benefits

Managing Partner: EngenderHealth; Associated Partners: FHI 360; Futures Institute; Johns Hopkins Bloomberg School of Public Health Center for Communication Programs; Meridian Group International, Inc.; Population Council

Grazie mille!